Wanbury Limited has announced a significant milestone in its product development efforts. The company has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for its new active pharmaceutical ingredient (API), Dextromethorphan.
Dextromethorphan is a key component in antitussive medications, commonly known as cough suppressants. The global market for Dextromethorphan formulations is substantial, valued at USD 2,500 million for FY24, with a robust growth rate of 7% over the previous year.
This CEP certification is a crucial step for Wanbury, as it paves the way for the company to begin commercial sales of Dextromethorphan API in European markets. The certification serves as a testament to the quality and compliance of Wanbury’s manufacturing processes with European standards.
With this development, Wanbury Limited is poised to expand its presence in the European pharmaceutical market, potentially capturing a share of the growing demand for cough medications. The company’s entry into this market segment could represent a significant opportunity for growth and increased revenue in the coming years.
